133
Views
4
CrossRef citations to date
0
Altmetric
Review

New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic

, , &
Pages 89-95 | Published online: 22 May 2019

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Konstantinos Katsoulis, Maria Kipourou & Stelios Loukides. (2022) Reduction/elimination of blood eosinophils in severe asthma: should there be a safety consideration?. Expert Opinion on Biological Therapy 22:3, pages 377-384.
Read now

Articles from other publishers (3)

Mona Al-Ahmad, Hassan Mobayed, Nasser Al Busaidi, Mohamed Nizam Iqbal, Saif Al Mubaihsi, Moussa Khadadah, Abeer Kassem, Mohamed Abuzakouk, Mateen Uzbeck, Ashraf Al Zaabi & Hisham Farouk. (2022) Severe asthma treatment patterns: A multicenter observational study in the Gulf region. World Allergy Organization Journal 15:5, pages 100647.
Crossref
Norio Kodaka, Chihiro Nakano, Takeshi Oshio, Takatomo Hirouchi, Manabu Satou, Masao Moroi, Toshiaki Oharaseki & Hiroto Matsuse. (2021) Successful treatment of an elderly patient with severe eosinophilic asthma and eosinophilic myocarditis using benralizumab. Geriatrics & Gerontology International 22:2, pages 175-176.
Crossref
Li-Yen Lee, Geena Suet Yin Hew, Meenu Mehta, Shakti D. Shukla, Saurabh Satija, Navneet Khurana, Krishnan Anand, Harish Dureja, Sachin Kumar Singh, Vijay Mishra, Pankaj Kumar Singh, Monica Gulati, Parteek Prasher, Alaa A.A. Aljabali, Murtaza M. Tambuwala, Lakshmi Thangavelu, Jithendra Panneerselvam, Gaurav Gupta, Flavia C. Zacconi, Madhur Shastri, Niraj Kumar Jha, Dikaia Xenaki, Ronan MacLoughlin, Brian G. Oliver, Dinesh Kumar Chellappan & Kamal Dua. (2021) Targeting eosinophils in respiratory diseases: Biological axis, emerging therapeutics and treatment modalities. Life Sciences 267, pages 118973.
Crossref